Renal Anemia Innovation Support and Expansion Act

H.R. 8177 · 116th Congress · Sep 4, 2020 · Lineage

A BILL

To amend title XVIII of the Social Security Act to remove from the list of drugs excluded from coverage under the Medicare prescription drug program prescription oral vitamins and mineral products indicated for the treatment of iron deficiency anemia in individuals with chronic kidney disease.

Section 1 Short title

This Act may be cited as the “Renal Anemia Innovation Support and Expansion Act” or the “RAISE Act”.

Sec. 2 Removing certain prescription vitamins and mineral products from the list of drugs excluded from coverage under the Medicare prescription drug program

Section 1860D–2(e)(2)(A) of the Social Security Act (42 U.S.C. 1395w–102(e)(2)(A)) is amended by inserting “other than subparagraph (F) of such section (relating to prescription vitamin and mineral products, except prenatal vitamins and fluoride preparations) if the prescription vitamin or mineral product is orally administered and is indicated for treatment of iron deficiency anemia in individuals with chronic kidney disease,” after “other than subparagraph (E) of such section (relating to smoking cessation agents),”.

Lineage

Sep 4, 2020viewing Introduced in House Mr. O'Halleran (for himself, Mr. Bucshon, Mr. Butterfield, and Mr. Mullin) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

Renal Anemia Innovation Support and Expansion Act

Section 1 Short title

Sec. 2 Removing certain prescription vitamins and mineral products from the list of drugs excluded from coverage under the Medicare prescription drug program

Cite this provision

Incoming references